Navigation Links
ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Date:10/28/2009

develop a clinical development program for maribavir;
  • approval of products which are currently marketed for other indications by other companies or new pharmaceuticals and technological advances to treat the conditions addressed by Vancocin or Cinryze;
  • fluctuations in wholesaler order patterns and inventory levels;
  • manufacturing, supply or distribution interruptions, including but not limited to our ability to acquire adequate supplies of Vancocin and Cinryze to meet demand for each product;
  • our plans to increase manufacturing capacity for Cinryze and the timing thereof;
  • changes in prescribing or procedural practices of physicians, including off-label prescribing of products competitive with Vancocin and Cinryze;
  • the timing of regulatory submissions and approvals;
  • actions by the FDA, EMEA and the Internal Revenue Service or other government regulatory agencies;
  • decreases in the rate of infections for which Vancocin is prescribed or decreases in the sensitivity of the relevant bacteria to Vancocin;
  • the timing and results of anticipated events in our clinical development programs; and
  • the timing and nature of potential business development activities related to our efforts to expand our current portfolio through in-licensing or other means of acquiring products in clinical development or marketed products.
  • There can be no assurance that we will conduct additional CMV studies in the future. The FDA or other regulatory authorities may prohibit any future studies with maribavir or alternatively may require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval. There can be no guarantee that we will be successful in gaining regulatory approval of maribavir for any indications. There can be no assurance that we will conduct additional studies or that we will be successful in gaining regulatory approval of Cinryze for ad
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related medicine technology :

    1. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
    2. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
    3. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
    4. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
    5. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
    6. ViroPharma Announces Discontinuation of HCV-796 Development
    7. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
    8. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
    9. ViroPharma to Present at the Natixis Bleichroeder Conference
    10. ViroPharma to Present at Three Upcoming Healthcare Conferences
    11. Accuray Incorporated to Present at 20th Annual Oppenheimer Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2014)... Takeda Pharmaceutical Company Limited ("Takeda") today announced ... of data from a 10-year epidemiology study to ... (U.S.) Food and Drug Administration (FDA), ... Ministry of Health, Labour, and Welfare (MHLW) / ... for pioglitazone containing medicines, including ACTOS (pioglitazone HCl). ...
    (Date:8/28/2014)... , Aug. 28, 2014  In anticipation of the upcoming ... being made available for the first time. Industry Overview: ... offers a snapshot of San Diego,s ... Highlighting everything from the latest employment statistics to current venture ... San Diego such a vital part of ...
    (Date:8/28/2014)... /PRNewswire-iReach/ -- Academy Leadership, an elite leadership training firm ... a case study highlighting one manager,s experience ... In September and October 2014, Academy Leadership affiliates are ... , Indianapolis , Salt Lake City , ... http://photos.prnewswire.com/prnh/20140828/140814 Leadership training for managers ...
    Breaking Medicine Technology:Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
    ... , FRIMLEY, England, December 8 ... Measures of Treatment Effectiveness,in the Trial, in Patients With Newly-Diagnosed Disease(1) , ... Later Stages,of the Disease on nilotinib (300mg Twice-Daily and 400mg Twice-Daily) Than ... Well Tolerated; Only a Small Number of Patients,Discontinued Due to Adverse Events(1) ...
    ... Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical ... cancer, inflammation and autoimmune diseases, today announced data from ... patients with B-precursor acute lymphoblastic leukemia (ALL). The data ... Annual Meeting of the American Society of Hematology (ASH) ...
    Cached Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4
    (Date:8/29/2014)... Edvance360, a leading provider of eLearning solutions, ... as well as 2011 winner and six-time-finalist for the ... announced that Brooke Education Services, Northwest Academy, Typewell, Dialysis ... Bureau of Canada (IAB Canada), StarSVCS, and HMG Plus, ... to welcome each new client to the growing Edvance360 ...
    (Date:8/29/2014)... 29, 2014 Floors of hospitals and ... wearing socks. Also, many patients are relegated to lying ... surgery recovery, Alzheimer’s, etc. Two inventors from Perrysburg, Ohio, ... patient safety. , This special pair of socks helps ... keeps patients who are relegated to beds or chairs ...
    (Date:8/29/2014)... a U.S. Food and Drug Administration (FDA)-approved treatment ... is as effective at reducing fracture risk as ... suppressing bone loss. With the use of wide- ... researchers carried out experiments at the U.S. Department ... Argonne National Laboratory that revealed an additional mechanism ...
    (Date:8/29/2014)... the Washington University School of Medicine have identified one ... providing important insight that could lead to new therapies, ... Cell Host & Microbe . , In work ... Photon Source, the researchers developed a detailed map of ... host protein that takes signaling molecules in and out ...
    (Date:8/29/2014)... August 30, 2014 Top10inaction, a professional ... conference providers in the online service industry for the ... global leaders Webex, GotoMeeting and Infinite. , With over ... have to determine which provider is ideally a good ... businesses search for compelling consumer goods and services agencies ...
    Breaking Medicine News(10 mins):Health News:Edvance360 Continues to Experience Growth in Corporate, K-12, Health, and Non-Profit Sectors 2Health News:Revealing a novel mode of action for an osteoporosis drug 2Health News:Top10InAction Reveals Best Web Conference Providers 2
    ... Highlights ... ... In recognition of Gynecologic Cancer Awareness Month, Planned Parenthood of the Rocky Mountains is ... screenings and treatments to help save their lives., , ,"We see firsthand at our ...
    ... , , ARLINGTON, Va., ... and Human Services Office of Inspector General (OIG) ignored the ... complex rehab, to seniors and people with disabilities who require ... Medicare Program: Supplier Acquisition Costs and Services" and dated August ...
    ... WASHINGTON, Sept. 3 Speaker Nancy Pelosi released the following statement ... "Any real change requires the inclusion of a strong public ... option is not included, it would be a major victory for the ... that a public option will keep the insurance companies honest. If someone ...
    ... VALLEY NATIONAL PARK, STOVE PIPE WELLS, Calif., Sept. 3 Jeff ... , will hike 40 miles per day through California,s Death Valley ... September 5, 2009, Sekerak hikes from Stove Pipe Wells to a ... to demonstrate the superior level of fitness attained through his program, ...
    ... , BROOMFIELD, Colo., Sept. 3 Embla(R) ... will acquire Covidien,s Sleep Diagnostic business. This includes the sleep diagnostic ... the transaction were not disclosed. Completion of the sale is subject ... entity will form the world,s largest company to focus entirely on ...
    ... YORK, Sept. 3 As millions of teens head back to school, ... , Teens are at a greater risk of than any ... lack of experience. Many of those crashes could be avoided with proper ... produces free driver education programs. , , NRSF spokesperson ...
    Cached Medicine News:Health News:Planned Parenthood Stresses Importance of Regular Checkups During Gynecologic Cancer Awareness Month 2Health News:Federal Study on Power Wheelchair Costs in Medicare Is Misleading and Ignores Costs of Required Services for Beneficiaries 2Health News:Federal Study on Power Wheelchair Costs in Medicare Is Misleading and Ignores Costs of Required Services for Beneficiaries 3Health News:One Man's Answer to the Health Care Crisis: Develop Extreme Fitness 2Health News:Embla(R) Systems Announces the Acquisition of the Sandman(R) Sleep Diagnostic Business from Covidien(R) - Creating the World's Largest Sleep Diagnostic Company 2Health News:Back to School Brings Risks to Young Drivers; Traffic Crashes Leading Cause of Teen Death, Says National Road Safety Foundation 2
    P-Series Cystourethroscope Short Bridge, examining...
    Short double-horn bridge for insertion of instruments...
    Designed for accurate articulation of flexible devices....
    ... Used for stone manipulation and removal in the ... basket to retain its shape following extreme torsion. ... capture by allowing the basket to open at ... stone. The tipless design reduces the likelihood of ...
    Medicine Products: